The Pharma Letter M&A roundup - February 2025

6 March 2025

Private equity firms acquiring assets were among the most eye-catching deals in pharma M&A during February.

Mitsubishi Tanabe Pharma and bluebird bio were both bought by investors during the month, while private equity firms Blackstone (NYSE: BX), Brookfield Corporation (TSX:BN) and Warburg Pincus are also in talks to acquire a majority stake in Hyderabad, India-based Gland Pharma from China's Shanghai Fosun Pharmaceutical (SHSE: 600196).

Big pharma companies Novartis (NOVN: VX) and AstraZeneca (LSE: AZN) announced acquisitions, too, with our table and graph below summarizing the month's activity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK